These are the calcitonin gene-related peptide (CGRP)-targeted therapies which have revolutionized the management of migraine [5], including monoclonal antibodies against the CGRP ligand or its receptor [6], and small molecules antagonists to the CGRP receptor, the gepants [7]. Here, CALCA is linked to migraine disorder.